Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 9:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 151 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Safety in Normal Volunteers Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

NCT03282513
View directory record Official record
Conditions
Hepatic Impairment
Interventions
AG-120 (Ivosidenib)
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Sep 7, 2026, 9:12 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Comparative Study of Quinine Sulfate in Healthy Patients and in Patients With Renal Impairment

NCT00785551
View directory record Official record
Conditions
Healthy, Renal Impairment
Interventions
quinine sulfate
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 7, 2026, 9:12 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis

NCT02502188
View directory record Official record
Conditions
Parapsoriasis, Healthy Volunteers
Interventions
CC-90005, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 7, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

NCT03565861
View directory record Official record
Conditions
Safety Issues
Interventions
Placebo, NP10679
Drug
Lead sponsor
Neurop Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Sep 7, 2026, 9:12 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus

NCT06787586
View directory record Official record
Conditions
Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
Interventions
ATTO-1310, ATTO-1310 Placebo
Drug
Lead sponsor
Attovia Therapeutics Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
11
States / cities
Encinitas, California • Rocklin, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 7, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Omnitram Pharmacokinetic Study In Healthy Volunteers

NCT02205554
View directory record Official record
Conditions
Pain
Interventions
Omnitram, Tramadol, Placebo
Drug
Lead sponsor
Syntrix Biosystems, Inc.
Industry
Eligibility
21 Years to 55 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 7, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis

NCT03922607
View directory record Official record
Conditions
Psoriasis
Interventions
ABBV-157, Placebo for ABBV-157
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Sep 7, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers

NCT01830764
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Red Light (PDT)
Drug
Lead sponsor
Dermira, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Sep 7, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

NCT04772885
View directory record Official record
Conditions
Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions
KT-474/Placebo, KT-474
Drug
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
14
States / cities
Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced Sep 7, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function

NCT02372084
View directory record Official record
Conditions
Hepatic Impairment
Interventions
osilodrostat
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 7, 2026, 9:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers

NCT00889252
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
contact lens with ketotifen, contact lens
Device
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
8 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 7, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers

NCT01755247
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Topical Gel Vehicle, 8% NVN1000 Topical Gel, 8% NVN1000 Topical Gel and moisturizer
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 7, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

NCT03464864
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 7, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-Human Safety and Dose-Finding Study of New Type-16 Human Rhinovirus (RG-HRV16) Inoculum in Healthy Volunteers

NCT01769573
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RG-HRV16, Placebo
Biological · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Sep 7, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers

NCT00787007
View directory record Official record
Conditions
Healthy
Interventions
S-equol, Placebo
Drug
Lead sponsor
Ausio Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Sep 7, 2026, 9:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Experimental Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray in Normal Volunteers

NCT02908620
View directory record Official record
Conditions
Anesthesia
Interventions
One spray CTY-5339-A, One spray CTY-5339-CB, Two sprays CTY-5339-A, One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo)
Combination Product · Drug
Lead sponsor
Cetylite Industries
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 7, 2026, 9:12 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial

NCT01011335
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Monovalent rAT, Monovalent rLukS-PV, Bivalent rLukS-PV / rAT, Placebo with adjuvant, Placebo
Biological
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Fort Sam Houston, Texas • Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Sep 7, 2026, 9:12 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788

NCT02255968
View directory record Official record
Conditions
Healthy
Interventions
EDP-788, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Sep 7, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

NCT03207425
View directory record Official record
Conditions
NASH
Interventions
EDP 305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 7, 2026, 9:12 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

NCT07205081
View directory record Official record
Conditions
Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
Interventions
ATTO-3712, Placebo
Drug
Lead sponsor
Attovia Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Encinitas, California • Saint Joseph, Missouri
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 7, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

NCT06858696
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Mavorixafor
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Montclair, California • Rialto, California • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 7, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788

NCT01999725
View directory record Official record
Conditions
Safety in Normal Volunteers
Interventions
EDP-788, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Sep 7, 2026, 9:12 AM EDT
Completed Phase 1 Interventional

Peyronie's Disease Treatment Protocol

NCT02072018
View directory record Official record
Conditions
Peyronie's Disease
Interventions
H-100, Placebo
Drug
Lead sponsor
Hybrid Medical
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Robbinsdale, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Sep 7, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers

NCT06086613
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
AGA2115, Placebo
Drug
Lead sponsor
Angitia Incorporated Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lake Forest, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Sep 7, 2026, 9:12 AM EDT